US venture capital company Third Rock Ventures has expanded its team by appointing a number of industry heavyweights.
The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies.
James Geraghty, who has spent 20-years at Genzyme, becomes entrepreneur-in-residence, while the former president of Lilly Research Laboratories, Steven Paul (pictured right), takes on an increased role at Third Rock with a position as a venture partner.
Also joining Third Rock as venture partners are Daniel Lynch (pictured right), a former CEO of ImClone Systems, and Alnylam’s CEO John Maraganore.
Robert Tepper, partner at Third Rock Ventures, said: “These leaders have demonstrated – through decades of experience – their ability to integrate science and business.
“The depth of their expertise across commercial, business development, R&D, drug discovery and product development will be invaluable to Third Rock as we focus on translating scientific innovation into exceptional companies that make a difference for patients.”